Ernexa Therapeutics Inc. (ERNA) Earnings Signals & AI Vibe Check
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Ernexa Therapeutics Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Ernexa Therapeutics Inc.'s filing signal
continuing negative.
earningsVibe SuperAnalyst™ Verdict:
CONTINUING NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-39.66%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Turned Positive
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Ernexa Therapeutics Inc. actually do?
Answer:
Ernexa Therapeutics Inc. is a preclinical-stage company focused on developing synthetic allogeneic iMSC (induced pluripotent stem cell-derived mesenchymal stem cells) therapies for cancer and autoimmune diseases. Its lead candidate, ERNA-101, targets platinum-resistant ovarian cancer and is designed to deliver pro-inflammatory factors directly to the tumor microenvironment. The company has advanced ERNA-101 through a successful pre-IND meeting with the FDA and anticipates an IND submission and Phase I clinical trial in 2026. Ernexa is also investigating ERNA-201 for autoimmune disorders like rheumatoid arthritis. The company is actively seeking strategic partnerships to co-develop or out-license its therapeutic assets and has secured a license for its iMSC technology platform from Factor Bioscience Limited.
Question:
What are Ernexa Therapeutics Inc.'s revenue drivers?
Answer:
The company has not generated revenue from product sales. Its historical revenue has been from a customer contract related to an exclusive option and license agreement, which was assigned to a third party in September 2024.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required